Cure8 research brief
A colon-targeted delivery system could allow an anti-inflammatory plant extract (Myrica esculenta) to reach the colon with minimal systemic exposure, which may be relevant for developing localized treatments for ulcerative colitis.
Researchers in drug formulation and delivery, clinicians interested in localized UC therapies, and pharmaceutical scientists.
The authors prepared a Myrica esculenta extract and used Eudragit E100 and S100 polymers to make CODESTM-based, pH-triggered tablets. Formulations were optimized with a central composite design; the lead formulation showed high drug content uniformity and in vitro release consistent with limited gastric/intestinal release and substantial colonic release.
In vivo roentgenography (imaging) in the study confirmed tablets stayed intact through the small intestine and released content at colonic pH. The study is formulation and early-stage (pharmaceutical development) research.
It demonstrates feasibility in controlled-release design and localization to the colon, but it does not provide clinical efficacy or safety data in people with ulcerative colitis.
This article reports pharmaceutical formulation work (in vitro dissolution and in vivo roentgenography) described in an abstract/full-text entry; it does not report clinical safety or efficacy in patients. The work demonstrates feasibility of pH-triggered colonic release using Eudragit polymers but further testing is required before clinical application.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer...
